Danaher to Acquire Abcam for ~$5.7B
Shots:
- Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash representing a 2.7% premium to the stock's last closing price making a total enterprise value of ~$5.7B incl. assumed indebtedness and net of acquired cash. The deal is expected to close in mid-2024
- Additionally, Abcam will operate as a standalone company within the Life Sciences segment of Danaher while mapping complex diseases and accelerating the drug-discovery process.
- Abcam focuses on delivering antibodies, reagents, biomarkers, and assays to address targets in biological pathways vital for progressing drug development and research in the life sciences sector
Ref: Danaher | Image: Danaher
Related News:- Danaher Receives S.Korean FTC's Conditional Approval for its $21.4B GE Biopharma Acquisition
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
